FDA reviews Qdenga vaccine

4 months ago 32
Suniway Group of Companies Inc.

Upgrade to High-Speed Internet for only ₱1499/month!

Enjoy up to 100 Mbps fiber broadband, perfect for browsing, streaming, and gaming.

Visit Suniway.ph to learn

Alexis Romero - The Philippine Star

June 3, 2026 | 12:00am

A doctor checks a blood sample of a dengue patient at the East Avenue Medical Center in Quezon City in this file photo from March 2018.

AFP

MANILA, Philippines — The Food and Drug Administration (FDA) is assessing a proposed dengue vaccine, Malacañang said yesterday, reminding the public to undertake precautionary measures against the mosquito-borne viral illness.

Developed by Japan-based Takeda Pharmaceutical Co., the Qdenga dengue vaccine’s efficacy is reportedly lower among children aged four to five years compared to those aged six and above, Presidential Communications Undersecretary Claire Castro said.

Data indicated the possibility of severe dengue serotype 3 risk among vaccinated persons who had not contracted dengue, she added.

Dengue cases nationwide decreased by 57 percent, with 48,151 cases posted this year from 110,924 in the same period last year.

Read Entire Article